| scholarly article | Q13442814 |
| P50 | author | Peter Lichter | Q2076661 |
| François Doz | Q56809901 | ||
| David T. W. Jones | Q58388511 | ||
| Richard Gilbertson | Q64746860 | ||
| Franck Bourdeaut | Q66360615 | ||
| Michael D. Taylor | Q88072573 | ||
| Christine Haberler | Q88178484 | ||
| André O von Bueren | Q88766377 | ||
| Andrey Korshunov | Q89166780 | ||
| Yoon-Jae Cho | Q90317000 | ||
| Stefan Rutkowski | Q90355738 | ||
| Marcel Kool | Q90637389 | ||
| Steven Clifford | Q90928957 | ||
| Paul A Northcott | Q91826566 | ||
| Scott L Pomeroy | Q92805532 | ||
| Antoinette Y N Schouten-van Meeteren | Q114726801 | ||
| Olivier Delattre | Q30119391 | ||
| Martin McCabe | Q37835209 | ||
| Jan Koster | Q39051477 | ||
| Stefan M. Pfister | Q39183179 | ||
| Marc Remke | Q43153350 | ||
| Magnus L Bäcklund | Q55458949 | ||
| Dannis G van Vuurden | Q56613322 | ||
| P2093 | author name string | David W Ellison | |
| V Peter Collins | |||
| Torsten Pietsch | |||
| Maria Schlanstein | |||
| P2860 | cites work | Molecular subgroups of medulloblastoma: the current consensus | Q24615271 |
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci | Q28236937 | ||
| beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee | Q28279527 | ||
| Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
| Subtypes of medulloblastoma have distinct developmental origins | Q28300616 | ||
| Altered neural cell fates and medulloblastoma in mouse patched mutants | Q28588056 | ||
| Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features | Q33366431 | ||
| A flexible R package for nonnegative matrix factorization | Q33624159 | ||
| FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma | Q34215755 | ||
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 | ||
| Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples | Q35837393 | ||
| Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct | Q35960250 | ||
| Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups | Q36460209 | ||
| Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells | Q36882529 | ||
| Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
| Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma | Q37002410 | ||
| MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma | Q39679776 | ||
| Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
| Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics | Q43631246 | ||
| Treatment of early childhood medulloblastoma by postoperative chemotherapy alone | Q46367739 | ||
| Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification | Q48194323 | ||
| Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. | Q53286039 | ||
| Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. | Q55462417 | ||
| Adult medulloblastoma comprises three major molecular variants. | Q55463035 | ||
| Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. | Q55468802 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | transcriptome | Q252857 |
| meta-analysis | Q815382 | ||
| medulloblastoma | Q1333608 | ||
| P304 | page(s) | 473-484 | |
| P577 | publication date | 2012-02-23 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | |
| P478 | volume | 123 |
| Q33665382 | A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience |
| Q91586791 | A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma |
| Q90843167 | A little piece of mind: best practices for brain tumor intraoperative consultation |
| Q34457533 | A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma |
| Q55460574 | A novel mechanism of oncogenesis in type 3 and 4 medulloblastomas. |
| Q35860191 | A standardized and reproducible protocol for serum-free monolayer culturing of primary paediatric brain tumours to be utilized for therapeutic assays |
| Q37365043 | ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma |
| Q36631618 | Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. |
| Q33772355 | Actionable molecular biomarkers in primary brain tumors |
| Q27015699 | Adaptations of energy metabolism during cerebellar neurogenesis are co-opted in medulloblastoma |
| Q36100967 | Adult medulloblastoma: A rare case report and literature review |
| Q26866408 | Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors |
| Q26829861 | An integrative view on sex differences in brain tumors |
| Q43213773 | Analysis of chromosome 17 miRNAs and their importance in medulloblastomas |
| Q36077998 | Anomalous vascularization in a Wnt medulloblastoma: a case report |
| Q47685017 | Astrocytes Promote Medulloblastoma Progression through Hedgehog Secretion |
| Q55461185 | Author reply: To PMID 23279053. |
| Q104079509 | Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma |
| Q36890856 | BAF complexes facilitate decatenation of DNA by topoisomerase IIα |
| Q92439644 | BCOR involvement in cancer |
| Q39050679 | BET bromodomain inhibition of MYC-amplified medulloblastoma. |
| Q38369383 | Beta-hairpin hydrogels as scaffolds for high-throughput drug discovery in three-dimensional cell culture |
| Q41431696 | Bimodal antagonism of PKA signalling by ARHGAP36. |
| Q64235666 | Bioinformatics Analysis of Key Genes and Pathways for Medulloblastoma as a Therapeutic Target |
| Q38805415 | Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy |
| Q36629427 | Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial |
| Q43132659 | Brain Tumor Epidemiology - A Hub within Multidisciplinary Neuro-oncology. Report on the 15th Brain Tumor Epidemiology Consortium (BTEC) Annual Meeting, Vienna, 2014. |
| Q34463432 | Brain neoplasms and coagulation-lessons from heterogeneity |
| Q99237709 | CAR T Cell Therapy for Pediatric Brain Tumors |
| Q52096226 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. |
| Q93177223 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 |
| Q47979443 | CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. |
| Q36172819 | CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence |
| Q36089590 | CNS Anticancer Drug Discovery and Development Conference White Paper. |
| Q35640979 | CRMP1 Inhibits Proliferation of Medulloblastoma and Is Regulated by HMGA1 |
| Q36644748 | CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants |
| Q48641521 | Can miRNA-based real-time PCR be used to classify medulloblastomas? |
| Q89699337 | Cancer cell stemness, responses to experimental genotoxic treatments, cytomegalovirus protein expression and DNA replication stress in pediatric medulloblastomas |
| Q48381540 | Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development |
| Q88467059 | Case-based review: pediatric medulloblastoma |
| Q47282131 | Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. |
| Q34642123 | Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review |
| Q34285237 | Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. |
| Q64884332 | Chromatin remodeling defects in pediatric brain tumors. |
| Q38539478 | Chromosomal heterogeneity and instability characterize pediatric medulloblastoma cell lines and affect neoplastic phenotype |
| Q36873451 | Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers |
| Q48348934 | Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. |
| Q31043687 | Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature |
| Q38756270 | Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation |
| Q51542148 | Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas. |
| Q38962343 | Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk |
| Q37727021 | Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma. |
| Q24310764 | Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease |
| Q64235523 | Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma |
| Q33638790 | Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes |
| Q41573477 | Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib |
| Q55409347 | Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report. |
| Q36840256 | Consensus Paper: Cerebellar Development. |
| Q35630417 | Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours |
| Q39629867 | Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome |
| Q37627692 | Cytogenetic prognostication within medulloblastoma subgroups |
| Q34895825 | DJ-1 is activated in medulloblastoma and is associated with cell proliferation and differentiation |
| Q34330397 | DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis |
| Q91719964 | DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas |
| Q28282708 | DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies |
| Q38743450 | DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis |
| Q52608478 | Data mining of pediatric medulloblastoma microarray expression reveals a novel potential subdivision of the Group 4 molecular subgroup. |
| Q36931136 | Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics |
| Q50051453 | Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. |
| Q38048582 | Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits |
| Q38909956 | Demographics, patterns of care, and survival in pediatric medulloblastoma |
| Q34859989 | Deregulated proliferation and differentiation in brain tumors. |
| Q47284266 | Desmoplastic Nodular Medulloblastoma in Young Children: A Management Dilemma. |
| Q48392818 | Development of an early induction model of medulloblastoma in Ptch1 heterozygous mice initiated with N-ethyl-N-nitrosourea |
| Q41366975 | DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets |
| Q34166553 | Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors |
| Q38214255 | Discovery and preclinical development of vismodegib |
| Q34553348 | Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. |
| Q24621907 | Dissecting the genomic complexity underlying medulloblastoma |
| Q35999183 | Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia |
| Q88580963 | Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population |
| Q38624646 | Distinctive localization and MRI features correlate of molecular subgroups in adult medulloblastoma. |
| Q40596524 | Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer |
| Q38194990 | Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent |
| Q91665138 | EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma |
| Q59795355 | EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers |
| Q38112088 | Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria |
| Q34658803 | Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway |
| Q26770345 | Energy metabolism in neurodevelopment and medulloblastoma |
| Q36820466 | Epigenetic Silencing of DKK3 in medulloblastoma. |
| Q47900778 | Epigenetic regulation in medulloblastoma |
| Q33572502 | Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation. |
| Q38836198 | Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells |
| Q90674933 | Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data |
| Q38845148 | Evasion of cell senescence in SHH medulloblastoma. |
| Q38652681 | Evolving molecular era of childhood medulloblastoma: time to revisit therapy |
| Q50900131 | Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. |
| Q42413394 | Expression Profile of Sonic Hedgehog Pathway Members in the Developing Human Fetal Brain |
| Q38781015 | Extracellular Vesicles in Brain Tumor Progression |
| Q34625129 | Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours |
| Q52714457 | FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. |
| Q52121739 | Familial Adenomatous Polyposis. |
| Q35646496 | Fast and reliable detection of toxic Crotalaria spectabilis Roth. in Thunbergia laurifolia Lindl. herbal products using DNA barcoding coupled with HRM analysis |
| Q39165033 | FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells |
| Q26825769 | G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues |
| Q28302285 | G-protein coupled receptor expression patterns delineate medulloblastoma subgroups |
| Q90288181 | GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis |
| Q47115561 | Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors |
| Q64232961 | Generation of the squamous epithelial roof of the 4 ventricle |
| Q57048305 | Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors |
| Q36142459 | Genetic and molecular alterations across medulloblastoma subgroups |
| Q36865020 | Genetic grouping of medulloblastomas by representative markers in pathologic diagnosis |
| Q27852966 | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition |
| Q43671177 | Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts |
| Q58804574 | Genomics of adult and pediatric solid tumors |
| Q49548506 | Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk and prognosis. |
| Q48300236 | Gliomatosis cerebelli, an infantile cerebellar neoplasm that exhibited diffuse infiltration without forming a mass |
| Q36612342 | Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations |
| Q39262034 | HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. |
| Q39175185 | Hedgehog Signaling: From Basic Biology to Cancer Therapy |
| Q90706218 | High expression of the transcriptional coactivator TAZ is associated with a worse prognosis and affects cell proliferation in patients with medulloblastoma |
| Q53622562 | Histological subtype of medulloblastoma frequently changes upon recurrence. |
| Q34773836 | ID3 contributes to cerebrospinal fluid seeding and poor prognosis in medulloblastoma |
| Q36965081 | IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma |
| Q61446577 | Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells |
| Q36356443 | Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. |
| Q48738953 | Identification of genes involved in the biology of atypical teratoid/rhabdoid tumours using Drosophila melanogaster |
| Q34415158 | Identification of suitable endogenous control genes for microRNA expression profiling of childhood medulloblastoma and human neural stem cells |
| Q38629781 | Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. |
| Q47555498 | Immunotherapy for brain tumors: understanding early successes and limitations |
| Q39828699 | Impact of tumor location and fourth ventricle infiltration in medulloblastoma |
| Q33633473 | Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma |
| Q38614779 | Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. |
| Q33756997 | Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. |
| Q43193981 | Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells |
| Q92326554 | Inhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth |
| Q47860981 | Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma |
| Q48766042 | Inhibitory potential of postnatal treatment with cyclopamine, a hedgehog signaling inhibitor, on medulloblastoma development in Ptch1 heterozygous mice |
| Q35684995 | Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. |
| Q91817106 | Insights into the Chemical Biology of Childhood Embryonal Solid Tumors by NMR-Based Metabolomics |
| Q37728564 | Integrated Proteomic and Transcriptomic-Based Approaches to Identifying Signature Biomarkers and Pathways for Elucidation of Daoy and UW228 Subtypes |
| Q40682183 | Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach |
| Q38120467 | Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. |
| Q57640952 | Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection |
| Q42378333 | Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. |
| Q47133309 | Jak2-mediated phosphorylation of Atoh1 is critical for medulloblastoma growth. |
| Q64119119 | L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma and |
| Q38820868 | Lentivirus-Mediated knockdown of tectonic family member 1 inhibits medulloblastoma cell proliferation |
| Q48120165 | Localization of SHH medulloblastoma in mice depends on the age at its initiation |
| Q64093106 | Long Noncoding RNAs: Emerging Players in Medulloblastoma |
| Q59335784 | Low Expression of miR-466f-3p Sustains Epithelial to Mesenchymal Transition in Sonic Hedgehog Medulloblastoma Stem Cells Through Vegfa-Nrp2 Signaling Pathway |
| Q55221354 | M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas. |
| Q35925281 | MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties |
| Q64947029 | MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. |
| Q36787522 | MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma |
| Q62492427 | MR Imaging-Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma |
| Q55452816 | MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art. |
| Q35211345 | MXD3 regulation of DAOY cell proliferation dictated by time course of activation |
| Q92310054 | MYC Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells |
| Q38123365 | Management of recurrent medulloblastoma in adult patients: a systematic review and recommendations |
| Q35550246 | Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. |
| Q86064194 | Medulloblastoma |
| Q91596369 | Medulloblastoma |
| Q36700543 | Medulloblastoma biology in the post-genomic era. |
| Q38376606 | Medulloblastoma development: tumor biology informs treatment decisions |
| Q37257512 | Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells |
| Q33763291 | Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy |
| Q54954567 | Medulloblastoma in the Molecular Era. |
| Q36493799 | Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? |
| Q35099027 | Medulloblastoma subgroups remain stable across primary and metastatic compartments |
| Q36360997 | Medulloblastoma with excessive nodularity: radiographic features and pathologic correlate |
| Q50089784 | Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis. |
| Q38263111 | Medulloblastoma-translating discoveries from the bench to the bedside |
| Q39225738 | Medulloblastoma: Molecular Classification-Based Personal Therapeutics |
| Q38791824 | Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm |
| Q64079587 | Medulloblastoma: optimizing care with a multidisciplinary approach |
| Q38233118 | Medulloblastoma: recurrence and metastasis |
| Q91826570 | Medulloblastomics revisited: biological and clinical insights from thousands of patients |
| Q37469904 | Medulloblastomics: the end of the beginning |
| Q52655039 | Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles. |
| Q35831225 | MethPed: a DNA methylation classifier tool for the identification of pediatric brain tumor subtypes. |
| Q91711195 | Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions |
| Q90126640 | MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3) |
| Q35744993 | MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting Neuropilin 1. |
| Q38889006 | MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells |
| Q39020346 | MiR-22 is frequently downregulated in medulloblastomas and inhibits cell proliferation via the novel target PAPST1. |
| Q38944728 | MiR-34a deficiency accelerates medulloblastoma formation in vivo |
| Q39228870 | MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). |
| Q41949639 | MicroRNA 22 regulates cell cycle length in cerebellar granular neuron precursors. |
| Q34104063 | MicroRNA-31 suppresses medulloblastoma cell growth by inhibiting DNA replication through minichromosome maintenance 2 |
| Q52678065 | MicroRNA-mRNA expression profiles associated with medulloblastoma subgroup 4. |
| Q48196262 | MicroRNAs Promote Granule Cell Expansion in the Cerebellum Through Gli2. |
| Q36387895 | Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours |
| Q39195507 | Modeling and Targeting MYC Genes in Childhood Brain Tumors |
| Q52358133 | Modeling cancer using patient-derived induced pluripotent stem cells to understand development of childhood malignancies. |
| Q39134342 | Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery |
| Q64234146 | Modulating native GABA receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death |
| Q36461766 | Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups |
| Q37573700 | Molecular Classification of Medulloblastoma |
| Q90270316 | Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma |
| Q33729693 | Molecular Testing of Brain Tumor |
| Q35192672 | Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma |
| Q38359284 | Molecular biology of pediatric brain tumors and impact on novel therapies |
| Q64087873 | Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas |
| Q36344704 | Molecular markers in pediatric neuro-oncology |
| Q38125031 | Molecular neuro-oncology in clinical practice: a new horizon |
| Q38971961 | Molecular pathology of paediatric central nervous system tumours. |
| Q92865416 | Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches |
| Q98226483 | Molecular subgrouping of medulloblastoma based on few-shot learning of multitasking using conventional MR images: a retrospective multicenter study |
| Q36977713 | Molecular subgroups of adult medulloblastoma: a long-term single-institution study |
| Q35101347 | Molecular subgroups of medulloblastoma |
| Q36367397 | Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. |
| Q24615271 | Molecular subgroups of medulloblastoma: the current consensus |
| Q37579203 | Molecular variants and mutations in medulloblastoma |
| Q90308673 | Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan |
| Q47827397 | Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). |
| Q47672070 | Multiple pilomatrixomas in a survivor of WNT-activated medulloblastoma leading to the discovery of a germline APC mutation and the diagnosis of familial adenomatous polyposis |
| Q33622402 | NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma |
| Q35982129 | Na,K-ATPase β1-subunit is a target of sonic hedgehog signaling and enhances medulloblastoma tumorigenicity |
| Q34103310 | Neuro-oncology: understanding the molecular complexity of medulloblastoma |
| Q92501760 | Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma |
| Q36168155 | Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth |
| Q26799880 | Not so Fast: Co-Requirements for Sonic Hedgehog Induced Brain Tumorigenesis |
| Q57295420 | Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma |
| Q38374250 | Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. |
| Q88732919 | Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers |
| Q59137750 | Numb Isoforms Deregulation in Medulloblastoma and Role of p66 Isoform in Cancer and Neural Stem Cells |
| Q91857038 | OTX1 and OTX2 Genes in Medulloblastoma |
| Q38755960 | OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma |
| Q38841348 | OTX2 expression contributes to proliferation and progression in Myc-amplified medulloblastoma |
| Q39239209 | OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels |
| Q47944360 | Obstacles to Brain Tumor Therapy: Key ABC Transporters |
| Q38214950 | Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer |
| Q56892727 | Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors |
| Q92147930 | Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma |
| Q89227992 | Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience |
| Q34500602 | Overcoming multiple drug resistance mechanisms in medulloblastoma. |
| Q34934082 | Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma |
| Q38734255 | Overexpression of minichromosome maintenance protein 10 in medulloblastoma and its clinical implications. |
| Q38435302 | Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma. |
| Q37656468 | PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas |
| Q37022200 | PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. |
| Q44135041 | Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas |
| Q35754390 | Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape |
| Q52148322 | Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. |
| Q38957473 | Pediatric brain tumor cell lines |
| Q21129295 | Pediatric medulloblastoma - update on molecular classification driving targeted therapies |
| Q36493813 | Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses |
| Q35135650 | Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma |
| Q38874298 | Personalized diagnosis of medulloblastoma subtypes across patients and model systems |
| Q58725240 | Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration |
| Q57057556 | Post-treatment maturation of medulloblastoma in children: two cases and a literature review |
| Q38583244 | Posterior fossa tumors in children: developmental anatomy and diagnostic imaging. |
| Q47288778 | Precision Medicine in Pediatric Neurooncology: A Review. |
| Q57043885 | Preclinical Models of Pediatric Brain Tumors-Forging Ahead |
| Q36480084 | Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors |
| Q64275194 | Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas |
| Q45052680 | Prognostic significance of Ror2 and Wnt5a expression in medulloblastoma |
| Q33764662 | Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort |
| Q88450978 | Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis |
| Q37004219 | Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis |
| Q55479624 | Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. |
| Q41952792 | Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma |
| Q48288270 | Proteomic analysis of human Sonic Hedgehog (SHH) medulloblastoma stem-like cells |
| Q35630706 | Proteomic profiling of high risk medulloblastoma reveals functional biology |
| Q57158811 | Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups |
| Q39365632 | Proton Beam Therapy for Pediatric Brain Tumor |
| Q44872362 | Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation. |
| Q33709483 | RITA displays anti-tumor activity in medulloblastomas independent of TP53 status |
| Q38194436 | RNA binding protein-mediated post-transcriptional gene regulation in medulloblastoma |
| Q98280890 | Radial shock waves prevent growth retardation caused by the clinically used drug vismodegib in ex vivo cultured bones |
| Q38537549 | Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program |
| Q39449209 | RalA is overactivated in medulloblastoma |
| Q37312706 | Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas |
| Q37636027 | Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis |
| Q53737190 | Refining medulloblastoma subgroups. |
| Q52095907 | Regulation of USP37 Expression by REST-Associated G9a-Dependent Histone Methylation. |
| Q30878032 | Relative cerebral blood volume from dynamic susceptibility contrast perfusion in the grading of pediatric primary brain tumors |
| Q38742012 | Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine |
| Q51230315 | Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4. |
| Q92154185 | Resolving medulloblastoma cellular architecture by single-cell genomics |
| Q38121136 | Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy |
| Q41989047 | Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases |
| Q36901551 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus |
| Q88737429 | Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial |
| Q43153279 | Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays |
| Q38268588 | Role of CXCL12 and CXCR4 in normal cerebellar development and medulloblastoma. |
| Q37256443 | Role of MYC in Medulloblastoma. |
| Q54782837 | Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. |
| Q38509205 | SHH inhibitors for the treatment of medulloblastoma |
| Q47840177 | SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis. |
| Q47851151 | STIL balancing primary microcephaly and cancer |
| Q91780113 | Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience |
| Q90003904 | Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol |
| Q91933328 | Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes |
| Q35611341 | Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma. |
| Q38645948 | Sexual dimorphism in glioma glycolysis underlies sex differences in survival |
| Q34117529 | Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males |
| Q36956174 | Signaling pathway and molecular subgroups of medulloblastoma |
| Q26827171 | Significance and therapeutic value of miRNAs in embryonal neural tumors |
| Q50744249 | Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma. |
| Q58795103 | Sonic Hedgehog Medulloblastoma Cancer Stem Cells Mirnome and Transcriptome Highlight Novel Functional Networks |
| Q36471378 | Sonic Hedgehog Signaling Drives Mitochondrial Fragmentation by Suppressing Mitofusins in Cerebellar Granule Neuron Precursors and Medulloblastoma |
| Q91452793 | Stalled developmental programs at the root of pediatric brain tumors |
| Q89207952 | Subfrontal recurrence after cerebellar medulloblastoma resection without local relapse: case-based update |
| Q36929844 | Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma |
| Q92663944 | Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma |
| Q57794783 | Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma |
| Q37316068 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma |
| Q38404462 | Targeted approaches to childhood cancer: progress in drug discovery and development |
| Q36618268 | Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors |
| Q38222028 | Targeted treatment for sonic hedgehog-dependent medulloblastoma. |
| Q57042397 | Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33 |
| Q35894565 | Targeting brain tumor cAMP: the case for sex-specific therapeutics |
| Q35246513 | Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma |
| Q26777997 | Targeting the Hedgehog Pathway in Pediatric Medulloblastoma |
| Q42361001 | The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know |
| Q36753692 | The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics |
| Q38421001 | The Emerging Molecular Foundations of Pediatric Brain Tumors |
| Q57474469 | The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer |
| Q39662585 | The Neuroradiological Spectra of Adult and Pediatric Medulloblastoma Differ : Results from a Literature-based Meta-analysis |
| Q96304778 | The Non-coding Side of Medulloblastoma |
| Q35542600 | The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. |
| Q89184115 | The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies |
| Q36490004 | The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants |
| Q38112071 | The adolescent and young adult with cancer: state of the art--brain tumor |
| Q41470815 | The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition |
| Q38206276 | The biologic era of childhood medulloblastoma and clues to novel therapies |
| Q38008153 | The clinical implications of medulloblastoma subgroups |
| Q96576668 | The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases |
| Q39438064 | The evolution of medulloblastoma therapy to personalized medicine |
| Q36334648 | The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies |
| Q38703533 | The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. |
| Q38231122 | The molecular landscape of pediatric brain tumors in the next-generation sequencing era. |
| Q33697463 | The prenatal origins of cancer |
| Q46155460 | The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival |
| Q38083796 | The role of chromatin remodeling in medulloblastoma. |
| Q38092920 | The role of microRNAs in medulloblastoma. |
| Q37033873 | The role of stem cells and progenitors in the genesis of medulloblastoma |
| Q36896072 | The role of the WNT/β-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs). |
| Q26782159 | The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma |
| Q28070264 | The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors |
| Q48000346 | The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities |
| Q37261835 | Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET) |
| Q30764536 | Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review |
| Q47132607 | Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma |
| Q46117209 | Tumor-associated macrophages in SHH subgroup of medulloblastomas |
| Q92289585 | UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts |
| Q36288376 | Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups |
| Q42647486 | Update on molecular and genetic alterations in adult medulloblastoma |
| Q90197653 | Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma |
| Q88766689 | Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma |
| Q27853187 | Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. |
| Q38164659 | Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma |
| Q34979270 | WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma |
| Q38053857 | What underlies the diversity of brain tumors? |
| Q34249356 | Widespread contribution of Gdf7 lineage to cerebellar cell types and implications for hedgehog-driven medulloblastoma formation |
| Q38952766 | Wnt activation affects proliferation, invasiveness and radiosensitivity in medulloblastoma. |
| Q90266281 | Wnt, Notch, and TGF-β Pathways Impinge on Hedgehog Signaling Complexity: An Open Window on Cancer |
| Q28080016 | Young investigator challenge: Cytomorphologic analysis of cerebrospinal fluid in 70 pediatric patients with medulloblastoma and review of the literature focusing on novel diagnostic and prognostic tests |
| Q64100105 | c-Myc activation promotes cofilin-mediated F-actin cytoskeleton remodeling and telomere homeostasis as a response to oxidant-based DNA damage in medulloblastoma cells |
| Q38973879 | miR-106b is overexpressed in medulloblastomas and interacts directly with PTEN. |
| Q36685489 | miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47 |
| Q38673795 | p53 and Meduloblastoma |
| Q33908911 | β-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. |
Search more.